Skip to main content
9,000+ open opportunities indexed

Search Grants — Free, No Account Required

Search federal, state, and foundation grants by keyword, state, or focus area. When you find a match, apply with our AI-assisted application builder.

1,556 grants foundClear search

24 grants worth up to $11.7M match your search

Enter your email to see grant names, funders, and application links

Ultrafine Particle Generator and Scanning Mobility Particle Sizer Integrated System

open

OD - NIH Office of the Director

ABSTRACT The University of Rochester has a long, internationally recognized history of research about the effects of airborne substances in the lungs and other organ systems. Indeed, Rochester is the birthplace of inhalation toxicology, as technology was developed here during the Manhattan Project to conduct studies on the effects of radionuclides. The infrastructure has grown over the decades into a dedicated Inhalation Exposure Facility (IEF) that supports basic and translational research about how airborne substances, by themselves or in combination with other stressors, contribute to cumulative health risk across the lifespan. Ambient air pollution is a mixture of particles, gases, and semi-volatile constituents that exhibits temporal and spatial variability in composition and concentration. It continues to be a significant threat to human health. Ambient pollutant fine and ultrafine (UFP, <100 nm in airborne diameter) particles are largely combustion- derived, e.g., from industrial and traffic sources, and have carbonaceous, inorganic salt, and metal/metal oxides compositional signatures. UFPs are of particular interest as drivers of adverse health effects due to their high number concentrations in air, large surface area-to-mass ratios, ability to deposit efficiently throughout the respiratory tract, and potential for transport to extrapulmonary tissues upon inhalation exposure. The study of UFP exposure-related health effects is an area of strength for the Rochester IEF. Its infrastructure has supported ground-breaking discoveries about the effects of UFP in the lung and extrapulmonary organ systems (cardiovascular, central nervous); transport of inhaled UFP to the brain via the olfactory system; perturbations in learning, memory, and impulsivity behaviors; and the mechanisms that lead to these adverse effects. The IEF tools for generating and characterizing UFP exposures are heavily utilized by multiple investigators who are funded by NIH and other agencies. To support these funded projects and to ensure that the research is conducted in a rigorous manner, replacement of and upgrades to the equipment that is used to generate, monitor, and characterize UFP-rich aerosols for inhalation exposures are urgently needed. Thus, this application seeks support to purchase a new integrated UFP aerosol generation and characterization system with modernized safety and monitoring features. This integrated system allows direct translation between species: knowledge about human exposures to UFP can be leveraged to conduct evidence-generating mechanistic studies in animal models or cell culture systems and, vice versa, health outcome data from basic science models can be translated to human-relevant exposures. Without this system that represents the state-of-the-art, the translatability of findings from UFP inhalation exposures is significantly weakened and, by extension, the impact of findings on evidence-based decision making.

Up to $145K
2027-06-14
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Uncovering determinants of pathogenic outcome versus protective responses in filovirus infections

open

NIAID - National Institute of Allergy and Infectious Diseases

ABSTRACT The filoviruses Ebola virus (EBOV) and Marburg virus (MARV), cause severe disease in humans with high case fatality rates. Advanced metagenomic analyses led to the discovery of previously unknown filoviruses from a range of animal species. Newly discovered filoviruses include Lloviu virus (LLOV) and Dehong virus (DEHV). While recent work on LLOV suggests that it might not pose a threat to human health, it is not known if DEHV can cause disease in humans. The discovery of novel filoviruses provides an excellent research avenue for determining the molecular correlates that define pathogenicity or protection by comparing closely related pathogenic and potentially nonpathogenic viruses. In this application, we propose to perform comparative studies with pathogenic (EBOV, MARV), likely nonpathogenic (Reston virus, LLOV), and filoviruses of unknown pathogenicity (DEHV). We will analyze potential determinants of filovirus pathogenicity across viruses, including replication kinetics (Aim 1), the magnitude of the virus-induced inflammatory response in macrophages (Aim 2), and virulence in two humanized mouse models (Aim 3). By integrating findings from all three aims, we will be able to define key molecular signatures of filovirus infection that have the potential to inform the assessment of the pathogenic potential of known and newly emerging filoviruses. In Aim 1, we will compare the replication kinetics of the various viruses in distinct cell types, which will inform about the virus-intrinsic and cell-dependent factors determining replication efficiency. We will perform RNA FISH analysis to gain insight into the earliest events of viral transcription and genome replication at single-cell level. Since viral replication kinetics determine the timing and rate of viral RNA production and protein expression, they may play a major role in shaping antiviral host responses and virulence. In Aim 2, we will comprehensively profile the phosphoproteomic/proteomic and transcriptomic changes in filovirus-infected human macrophages to map the differences in the host response signatures induced by pathogenic and nonpathogenic viruses. These analyses will be accompanied by mechanistic studies aimed to dissect the molecular mechanisms of filovirus-induced immune activation using knockdown cells and targeted inhibitor approaches. In Aim 3, we will comparatively assess the ability of the various filoviruses to cause disease in two human immune system (HIS) mouse models. This includes state-of-the-art histopathological analysis of the tissues including spatial transcriptomics. Our multidisciplinary team combines expertise in filovirus biology, virus-induced activation of innate immune cells, omics analysis, humanized mouse models, and histopathology of filovirus-infected tissues. We are therefore well positioned to perform the proposed work.

Up to $817K
2031-05-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Uncovering interactions between bioderived nanomaterials and water in novel dental adhesives: strategies for reduced moisture sensitivity

open

NIDCR - National Institute of Dental and Craniofacial Research

Project Summary The overarching goal of this R03 proposal is reduce the moisture sensitivity of dental adhesives by incorporating cellulose nanocrystals (CNCs). This work is motivated by prior research in related engineering applications (e.g., pressure sensitive adhesives, coatings) demonstrating that CNCs decrease moisture sensitivity of polymeric matrices. Despite this prior art, systematic investigation of CNC impact on dental adhesive materials has yet to be undertaken. This constitutes a major gap, as moisture sensitivity is a significant contributor to the high rate of secondary caries and therefore identifying benign materials that can address this issue is of utmost importance. Furthermore, the proposed specific aims will determine fundamental interactions between CNCs and water, determining if ‘bound’ water within a polymerized adhesive delays or eliminates water-mediated degradation mechanisms. I am qualified to lead this project, as previous and ongoing work from my research team investigates reduced water sensitivity in food packaging and adhesive materials modified with cellulose nanomaterials. Furthermore, my expertise in photopolymerized polymer networks employed as dental materials complements this expertise and makes me uniquely qualified to oversee this investigation. Building upon this foundation and expertise, the overarching hypothesis for this proposal is that long-term stability of the adhesive layer will be enhanced when CNCs are uniformly incorporated and distributed within a photopolymerized dental adhesive. This project consists of two Specific Aims. In Specific Aim 1, I will determine how the distribution of CNCs varies based on the composition of model self-etch adhesives, and how this distribution impacts moisture sensitivity, network properties, and adhesive performance when exposed to moisture. This is motivated by the high degree of heterogeneity associated with currently employed adhesive systems. In Specific Aim 2, different surface functionalizations will be explored to optimize and modify the distribution of CNCs within adhesive networks and potentially improve the impact of these additives on adhesive performance. Given the heterogeneous nature of adhesive materials, I expect surface functionalization will enable more effective distribution. This area of research constitutes a new domain at this early-stage of my career, and thus the results from this award will serve as motivation to investigate a more diverse range of bio-sourced nanomaterials (e.g., functionalization, geometries) for restoration systems where biomaterial-water interactions need to be tailored.

Up to $299K
2028-02-29
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Uncovering Mechanisms Contributing to Enhanced NeuroHIV with Cocaine Use

open

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY Cocaine use disorder (CUD) is highly comorbid in people with HIV (PWH) and can accelerate infection, alter neuropathology, and exacerbate cognitive decline despite antiretroviral therapy (ART). Many of these effects are due to the infection and dysregulation of CNS-associated myeloid cells, especially microglia, which comprise a significant reservoir in this compartment. However, the precise mechanisms by which cocaine (Coc) dysregulates microglia to enhance HIV infection are unclear, partly due to the lack of translationally relevant human microglial models suitable for mechanistic evaluation of Coc-mediated changes in viral dynamics. Classically, Coc has been thought to act by blocking dopamine transporter (DAT) activity, exposing microglia to aberrantly high dopamine concentrations. Our data show that dopamine can increase HIV infection and inflammation in microglia and other myeloid cells. However, recent data show that Coc has other mechanisms of action beyond the modulation of dopaminergic tone, involving the ER protein sigma1 (σ1), which has diverse cellular functions including the modulation of cellular stress pathways such as the unfolded protein response (UPR). Viruses, including HIV, can exploit the UPR to amplify stress-induced protein production in the host cell, enhancing viral replication. Our preliminary studies indicate that Coc’s effects on σ1 may drive a Coc-mediated increase in HIV infection in microglia, potentially through increased stress response and independent of dopamine’s effects. My preliminary data show that both Coc and σ1 agonists increase HIV replication in human inducible pluripotent stem cell (iPSC)-derived microglia (iMg). These effects are blocked by σ1 antagonism but not by inhibition of DAT or dopamine receptors. We also show increased σ1 protein expression and recruitment to the ER/nuclear envelope space in HIV-infected iMg treated with Coc, and preliminary single-cell RNAseq data suggest changes in the UPR. Therefore, we hypothesize that Coc-mediated activation of σ1 increases HIV infection of microglia via activation of the UPR. In Aim 1, we will test the involvement of σ1 in driving Coc-mediated changes in HIV infection of iMg using pharmacological and genetic modulation, and we will also confirm the absence of dopaminergic involvement. We will assess changes in viral dynamics using AlphaLISA and immunofluorescence (IF) high-content imaging. In Aim 2, we will test the hypothesis that Coc induces greater σ1 activity in the presence of HIV infection utilizing confocal and high-content IF imaging of σ1 subcellular localization in cellular compartments like the nuclear envelope, ER, and mitochondria-associated ER membrane. Movement of σ1 to these compartments is a feature of σ1 activation. In Aim 3, we will use single-cell RNAseq to test the hypothesis that Coc-induced σ1 activity drives increased HIV infection in iMg via upregulation of UPR genes. The results from these experiments will not only define novel interactions between HIV and σ1 that could reveal new antiretroviral targets but will also broadly inform on the role of σ1 in microglia and potentially identify biomarkers for prevention strategies against CUD and its associated comorbid diseases.

Up to $49K
2028-02-18
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Uncovering the Role of Intrinsically Disordered Regions in Regulating FOXG1-Chromatin Binding Dynamics

open

NIGMS - National Institute of General Medical Sciences

Project Summary/Abstract The forkhead box (FOX) family of transcription factors (TFs) regulate key biological processes across eukaryotes. One member, FOXG1, functions as a transcriptional repressor which regulates neurodevelopment within embryonic brains, and has been implicated in a range of neurodevelopmental disorders. The FOX family of TFs is defined by the presence of a conserved DNA-binding domain (DBD). The molecular mechanisms of this DBD on its own, and how mutations to this region impair its function and lead to disease, have been well studied. However, how the intrinsically disordered regions (IDRs) outside of the folded DBD influence FOX TF function remains understudied. There is a critical need to understand the role of these IDRs given that dozens of disease-associated mutations have been identified within the IDRs of FOXG1. In the proposed work, we aim to investigate the role of IDRs on FOXG1 chromatin binding, nuclear organization, and function in gene regulation. My preliminary data have revealed that FOXG1 forms nanoscale clusters in nuclei of live cells which drives its tight binding to chromatin. However, a disease-associated variant of FOXG1, which has truncations within its central IDR, no longer forms DNA-associated clusters. Additionally, I found that FOXG1 forms biomolecular condensates via phase separation which contributes to its association with DNA. Biomolecular condensates are dynamic structures often formed through IDR-mediated phase separation and have been recently implicated as an underlying mechanism for TF clustering in vivo to regulate gene expression at specific genomic loci. Intriguingly, we found that mutations within the same central IDR of FOXG1 which show a loss in nuclear clustering also show a loss of phase separation. We have identified a conserved enrichment of aromatic amino acids within the central IDR of FOXG1 using a state-of-the-art sequence analysis approach in collaboration with Dr. Rohit Pappu’s group at WashU. I have determined that these conserved aromatic residues are critical for FOXG1 phase separation, nuclear clustering, and chromatin association. From this preliminary data, I hypothesize that FOXG1 utilizes IDR-driven phase separation to form nuclear condensates which directly regulate its chromatin binding and function as a transcriptional repressor. We propose to test this hypothesis with a series of computational, biophysical, and cellular approaches designed to 1) identify critical sequence features within FOXG1 IDRs and predict their function on phase separation and chromatin binding, 2) quantify the effects that individual IDRs and critical amino acid residues have on FOXG1 phase separation, 3) determine how FOXG1 IDRs influence its DNA binding strength at a single-molecule level both in vitro and in cellulo, and 4) identify the role of FOXG1 IDRs in transcriptional repression. Collectively, the results from this study will provide critical insights from single-molecule to mesoscale levels into how IDRs regulate FOX TF activity and how mutations in these regions can lead to disease.

Up to $77K
2029-06-30
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Understanding how T cell receptor recognition of peptide ligands shapes memory CD8+ T cell programming

open

NIAID - National Institute of Allergy and Infectious Diseases

Abstract CD8+ T cells are unique in effective sensing and killing of intracellular pathogen-infected cells and tumor cells. Because current vaccines are designed to induce high titer pathogen-specific antibodies for host protection, new vaccines focused on promoting effective memory CD8+ T cells are needed. Since a single naive CD8+ T cell has the potential to give rise to multiple types of progenies, it is essential to understand how naive T cells are primed to form distinct effector and memory cells. It is generally accepted that the strength of cognate antigen (Ag) stimulation determines the size of the primary response and of the memory cell pool, and that strong cognate Ag signals coupled with robust co-stimulation and cytokines altogether drive naive CD8+ T cells towards an effector rather than a memory cell fate. The current dogma also states that cognate Ag stimulation does not lead to functionally distinct subsets of memory CD8+ T cells. In contrast, however, we recently discovered that the strength and the stability of cognate Ag/MHC interactions with the T cell receptor (TCR) determine the development of memory cell functional characteristics, in particular stem-cell associated characteristics, through epigenetic imprinting. Stem cell memory CD8+ T (TSCM) cells have been shown to exhibit superior functional features, progeny potential, self-renewal capacity and longevity. Using state of the art conditional mouse models, high dimensional spectral flow cytometry, lentiviral-based inducible gain or loss of function experiments, and computational modeling approaches, we will define the features of T cell epitopes, key TCR structural modes of recognition, TCR signaling pathways, genetic and epigenetic regulators that enhance the differentiation of TSCM cells in vivo. We will validate our findings in models of chronic infections and tumors. This research directly impacts the rational design of more effective vaccines and adoptive T cell transfer therapies.

Up to $781K
2030-12-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Understanding the Impact of Micro- and Nanoplastics on Preterm Birth

open

NIEHS - National Institute of Environmental Health Sciences

Preterm birth (PTB) affects 10% of pregnancies globally, with rates rising 12% between 2014-2022, incurring healthcare costs exceeding $25 billion annually in the US alone. While inflammation is a known trigger of PTB, the environmental factors driving this inflammatory response remain poorly understood. A critical knowledge gap exists in understanding how emerging environmental contaminants, particularly micro- and nanoplastic (MNP) particles, associate with PTB and alter placental immune function. Our preliminary data provide compelling evidence that MNPs bioaccumulate in human placentae at concentrations 23.9 times higher than in blood. Using pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS), we found significantly elevated MNP levels in preterm versus term placentae (224.7 vs 175.5 µg/g tissue; p=0.0032), with specific polymers showing 17-157% higher concentrations in preterm cases. The long-term objective of this research is to establish how environmental MNP exposure correlates with adverse pregnancy outcomes and identify modifiable risk factors for PTB prevention. Leveraging our completed longitudinal pregnancy cohort study (the Bacteria and Birth Study; BaBs Trial, n=585; PTB=103, term=367) with comprehensive maternal-infant biospecimens collected from first trimester through 6 weeks postpartum (>93,000 samples), we will: Aim 1) Define temporal patterns of MNP accumulation by quantifying 12 environmentally relevant polymers in maternal blood, urine, placental tissue, and cord blood (n=3,500 specimens) using Py- GC/MS, while integrating data on other environmental toxicants to establish exposure signatures that predict PTB risk; and Aim 2) Characterize the pathophysiology of MNP-associated placental dysfunction through systematic analysis of inflammatory markers (n=1,200 samples), histopathological changes (n=351 placentae), and immune cell distributions mapped by spatial transcriptomics (n=30 placentae). This comprehensive molecular and cellular characterization will establish the foundation for future mechanistic studies using animal models and in vitro systems. This research is innovative in challenging current paradigms of PTB etiology while introducing state-of-the- art methods to track environmental exposures during pregnancy. Our unique approach combines advanced analytical capabilities (Py-GC/MS- submicron plastics detection) with high-resolution spatial profiling to reveal how MNP exposure correlates with altered maternal-fetal immune balance. Success will establish: 1) The first longitudinal assessment of MNP accumulation patterns during pregnancy; 2) Novel biomarkers for identifying at- risk pregnancies; and 3) Key molecular and cellular changes associated with MNP accumulation in human placentae. These findings will directly inform the design of future mechanistic studies while directly providing evidence-based guidance for reducing harmful exposures during pregnancy, particularly benefiting vulnerable populations disproportionately affected by PTB.

Up to $640K
2031-01-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

University of Mississippi Medical Center MSTP

open

NIGMS - National Institute of General Medical Sciences

Project Summary The University of Mississippi Medical Center (UMMC) is home to the State’s only academic health science center and has a rich history of high-level biomedical research. As the States only level 1 trauma facility, level IV NICU, Children’s Hospital and Cancer Care Program, Sickle Cell Anemia Program, Transplant Program, and Bone Marrow Transplant Unit, our Hospitals and Clinics treat the most critically ill in Mississippi. In addition, the population of patients consists of the most at risk socioeconomic backgrounds. There is a great need to increase the number of physician scientists trained on the front lines where social and economic determinants greatly impact the health care of our residents. Therefore, the goal of this proposal is to establish and grow the University of Mississippi Medical Center MSTP in order to have a long-term impact to increase clinician scientists uniquely trained to tackle the most challenging problems that our health care system faces. Recognizing the exceptional resources, faculty, and environment at UMMC, leadership heavily invested in the MD/PhD program, setting the groundwork for support of the next generation of MD/PhD students. Over the last 5 years, 10 MD/PhD students have graduated from a variety of graduate programs supported by the School of Graduate Studies that include Cellular and Molecular Biology, Microbiology and Immunology, Experimental Therapeutics and Pharmacology, Neuroscience, Physiology, Biomedical Materials Science, and Population Health. Nearly 80 program faculty provide perspectives from all backgrounds and range from junior to established investigators that have trained over 300 PhD students. State of the art equipment, infrastructure, and research cores established largely by NIGMS funded Centers for Biomedical Research Excellence and the Mississippi Center for Clinical and Translational Research provide an optimal training environment where students can learn whole animal physiology, -omics approaches to understanding disease mechanisms, cell and molecular biology techniques, population health and more. Finally, recruitment strategies and geographical location make UMMC the ideal home to meet NIH goals to train physician scientists that represent a wide range of socio-economic backgrounds.

Up to $136K
2031-06-30
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit

open

NIAID - National Institute of Allergy and Infectious Diseases

The University of North Carolina (UNC) Global HIV Prevention and Treatment Clinical Trials Unit (CTU) has a well-established record of high quality, innovative clinical research, strong network and scientific leadership. The CTU engages with critically important populations infected with and at high risk of HIV in southeastern US, southern Africa and southeast Asia. Our CTU is led by three experienced principal investigators (Joseph Eron MD, Mina Hosseinipour MD and David Wohl MD) and will support all four NIH Clinical Trials Networks (CTN); Adult Therapeutic Strategies, HIV Prevention, Vaccine Prevention and Pediatric, Adolescent and Maternal Therapeutic Strategies. Our four experienced Clinical Research Sites (CRS) include Chapel Hill CRS (Adult Strategies, Prevention and Vaccine CTN) led by Dr. Wohl, Greensboro CRS (Adult Strategies, Prevention and Vaccine CTN) led by Cornelius Van Dam MD, Malawi CRS (all four CTN) led by Lameck Chinula MD and Vietnam CRS (Adult Strategies, Prevention and Vaccine CTN) led by Vivian Go PhD. Participants with HIV include those newly diagnosed (including with acute infection), PWH stably suppressed on therapy, PWH with adherence challenges to care or medication, and PWH with drugresistant HIV. We will enroll PWH at risk for comorbidities and PWH or without HIV including those with co-epidemic pathogens such as tuberculosis (TB) and Hepatitis B virus (HBV) which affect USA populations but the higher disease prevalence in Malawi and Vietnam allows research efficiency. We have skilled, experienced clinical and translational investigators working hand-in-hand with junior investigators in US and international settings, who will engage and execute the network scientific agenda. A globally representative set of senior scientists and public health leaders on our Scientific and Strategic Advisory Group advise the CTU leadership team. The CTU administration has a highly organized structure that is responsive to our research teams and CRSs. Each CRS engages the communities representing the affected populations in an interactive, openminded way. State-of-art communication and experienced, outstanding and well-organized laboratory, pharmacy, regulatory, quality and data management support the CTU, CRSs. Using this robust framework the UNC Global CTU is positioned optimally to continue our scientific, and network leadership and clinical trials support to all four NIH HIV networks, contributing to the elimination of HIV and significant co-infections in the USA and globally.

Up to $1K
2027-11-30
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

US Army Combat Capabilities Development Command Broad Agency Announcement

open

ACC APG - Natick

The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding &amp; Equipment Ration development, field feeding systems Soldier Protection &amp; Survivability Headborne protection, modular armor, chemical/biological protection, nanotechnology Modeling &amp; Simulation Soldier effectiveness, operational survivability Human Performance &amp; Biomechanics Body-worn systems, hand-held devices, soldier-centric sensors Expeditionary Maneuver Support Energy efficiency, EMI/EMP protection, battlefield mobility Aerial Delivery Advanced airdrop systems for personnel and cargo Simulation &amp; Training Technology Medical training, AI-based battlefield visualization, cyberspace warfare training This Broad Agency Announcement (BAA) is intended to fulfill requirements for scientific study and experimentation directed toward advancing state-of-the-art technologies and/or increasing knowledge and understanding as a means of eliminating current technology barriers. This BAA DOES NOT focus on specific systems or hardware solutions. This BAA identifies DEVCOM SOLDIER CENTER research/exploratory development areas of interest and provides prospective offerors information on the preparation of proposals along with proposal evaluation factors. The Government may award purchase orders, contracts, grants, cooperative agreements, or other transactions against this BAA. Read the Full BAA &amp; Submission Guidelines: On SAM.gov https://sam.gov/opp/e8c7609f0f154df4afda846595bca888/view

2030-02-27
other

Free to search & build · $99 one-time to unlock the application pack · No subscription

Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans

open

NIH

Background: How can we apply the community health worker (CHW) model to help both care partners and Veterans with serious illness in rural areas? Little is known about this approach. We will test a VA-supported intervention successfully piloted in the Durham VA and surrounding rural communities in 2021. VA’s Office of Rural Health, Caregiver Support Program and National Social Work Office are aware and support this work. Significance: Clinically, this work will help improve care for rural Veterans with serious illness by supporting care partners in their caregiving role in the community thus bolstering the care of Veterans receiving primary support from care partners in rural areas. A strength of our intervention is that it adapts and extends a successful model of individualized support commonly used outside of the VA. This approach maximizes the potential for sustainability, broad dissemination, and care delivery impact across the VA. This work will be generalizable. Strategically, this SDR proposal responds to the National Academies report recommending all health systems, including VA, develop processes to routinely identify, assess, and support needs of care partners. Our project meets rural health access, long-term care/aging, engagement science, and caregiving HSR priorities for investigator-initiated research focused on rural populations. Additionally, our proposed efforts fit squarely with the VA’s Rural Health State of the Art conclusion that we must expand VA partnerships in the community and help Veterans and their families understand their options for care and support in the community and at the VA. Innovation & Impact: This project is innovative because of its focus on social and practical needs of care partners, advances the science of community engagement in VA care and support, and situates a care partner- focused community health worker model squarely in the VA system for the first time. The entire project is guided by a Community Advisory Board (CAB) composed of social service, serious illness care, and rural care experts plus Veterans and care partners with lived experience. Specific Aims: Aim 1. Determine CHW effectiveness in reducing care partner burden, increasing Veterans' well-being, and increasing care partner-Veteran satisfaction with VA care in the intervention group compared with the usual care (CSP) group: We will apply our feasible CHW intervention to a larger sample, randomized control trial. (Hl) Care partners randomized to the intervention group will have lower mean Zarit-12 scores at 6 months compared to the control group. (H2) Care partners and Veterans randomized to the intervention group will have higher mean 1-item CAHPS Global Satisfaction scores at 6 months compared to the control group. (H3) Veterans randomized to the intervention group will have higher mean Warwick Edinburgh Mental Well- Being scores at 6 months compared to the control group. Aim 2: Following intervention, explore Veterans' and care partners' experience of care and support using subgroup semi-structured interviews in the intervention group. We then facilitate CAB Delphi Method sessions (including study Veterans, CHWs, and care partners) exploring Aims 1/2 data using equity-focused intervention mapping for wider implementation. Aim 3: Conduct budget impact analysis from the VA perspective to evaluate cost-drivers and assess feasibility to inform adaptation and implementation of the intervention within Durham VA Health Care System. Methodology: Two-arm randomized control trial using validated measures. We follow this using qualitative exploration with participants plus a Delphi method exploring implementation with the community advisory board and participants. We end with a unique business impact analysis of the intervention. Next Steps/Implementation: We are supported/advised by VA’s Office of Rural Health and Caregiver Support Program in Durham, NC with additional advisement from National Social Work Office, Chaplaincy, Palliative Care, county Veteran Services and Area Agencies on Aging (see LOS). If successful, this intervention can be added to the options available from CSP to support rural care partners and their seriously ill Veterans.

2029-09-30
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Using Computer Vision to Improve the Evaluation of Dysplasia in Inflammatory Bowel Disease

open

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

This study aims to develop new methods for detecting pre-cancerous dysplasia on colonoscopy and histology in patients with inflammatory bowel disease (IBD). IBD is associated with a higher incidence of colorectal cancer compared to the general population. However, IBD dysplasia is more difficult to detect on colonoscopy because lesions are flat, irregular in shape, and coincide with inflammation. In efforts to combat visualization problems, most gastroenterologists continue to perform random mucosal biopsy for increased sensitivity of dysplasia detection on colonoscopy. Accessory measures to help enhance dysplasia detection including high- definition endoscopy, dye chromoendoscopy, and narrow band imaging require extensive expertise, increase procedure duration, and have not been definitively shown to improve dysplasia detection rates. In addition to difficulty detecting dysplasia on colonoscopy, pathologists face similar ambiguity when evaluating dozens of biopsies provided from every colonoscopy. Beyond reviewer fatigue, pathologists are challenged to separate inflammation from dysplasia and the grade of severity, typically requiring referral to experts at high volume centers for second opinion review. Machine learning and computer vision methods are well suited to address clinician limitations in detecting visual features of IBD-related colonic dysplasia. Our multi-disciplinary team’s prior work developing methods to improve endoscopic disease activity assessments and quantify histologic imaging using machine learning will be adapted and applied to dysplasia detection in this proposed project. We will pursue three aims to achieve our goal of determining whether computer vision models can match or exceed the diagnostic ability of experts for detecting dysplasia on colonoscopy and histology. Aim 1 will build computer vision models trained to infer histologic ground truth using endoscopic imaging for detecting the presence of dysplasia on standard colonoscopy video from multiple centers. Methods will incorporate both still image classifier pipelines and new generative diffusion-based model architectures for full video analysis. Aim 2 will evaluate the performance of both experts and new FDA-approved AI assistant tools in colonoscopy for detecting dysplasia on colonoscopy, comparing results to best performing video-based dysplasia models. Finally, Aim 3 will apply computer vision quantitative histology to predict the presence of dysplasia on routine colonic biopsy, leveraging state-of-the-art histologic image segmentation methods for both enhanced pathologist annotation and modeling. Optimized dysplasia model performance will be tested and piloted in a real-world digital pathology workflow to evaluate the feasibility and performance of automated dysplasia detection in clinical practice. We expect these advancements will transform IBD dysplasia assessment by eliminating the need for cumbersome mucosal interrogation methods, improving accuracy of dysplasia detection, personalizing dysplasia surveillance and management, and providing a deployable technologic solution to elevate the quality of IBD care rendered by less-experienced clinicians.

Up to $778K
2029-12-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Using State-of-the-Art Technologies and Murine Models for Novel cGVHD Therapies

open

NHLBI - National Heart Lung and Blood Institute

Our primary goal is to acquire new insights into chronic GVHD (cGVHD) pathobiology to create new therapies to limit fibrosis. We’ve shown that T:B cell engagement can initiate cGVHD by causing pathogenic αhost immunoglobulin (Ig) deposition that exacerbates tissue injury, recruits monocytes (monos) and TGFβ-secreting macrophage (Macs), and stimulates fibroblast/myofibroblast/endothelial cell pro-fibrinogenic cytokines. Our central hypothesis is that developing effective αfibrotic therapies requires greater elucidation of tissue cellular mechanisms and dynamic evolution processes that culminate in cGVHD. We will use state-of-the-art techniques in valid mouse models to expose cGVHD vulnerabilities. Tissues will be obtained at an early and late timepoint from cGVHD mice with bronchiolitis obliterans (BO) or scleroderma (Scl) to assess cGVHD progression in lymphoid and cGVHD organs. In an innovative, scientifically and technologically unprecedented, approach we will interrogate cGVHD mechanisms in BO and Scl models by spatially and temporally resolving and integrating proteomics with whole genome transcriptomics at a single cell resolution within histopathological regions of interest. This will result in a spatiotemporal atlas mapping how specific cells drive cGVHD disease progression in both lymphoid and target tissues; an invaluable tool for future studies. Our specific aims will test the hypotheses that: Aim 1. Interrogating T cell:B cell crosstalk at cGVHD tissue sites will lead to novel therapeutics and individualized applications. During the mechanistic discovery phase, we will infuse bifunctional (suppressive and cytolytic) αCD19 scFv chimeric antigen receptor (CAR19) Tregs to preclude B cell support of pathogenic IgG secretion, leveraging our murine cGVHD/BO cell atlas to assess the means by which these cells disrupt cGVHD progression. Aim 2. cGVHD tissue injury recruits monos that evolve into αinflammatory, pro-fibrinogenic Macs and engagement with fibroblasts/myofibroblasts to initiate fibrosis. Coupling mono and Mac reporter and deleter donor mice with spatiotemporal multi-omics, we will define the mechanisms by which monos and Macs enter cGVHD tissues and pro-fibrotic cytokines are produced, leading to new and key therapeutic targets. To halt fibrosis, mannosylated lipid nanoparticles with TGFβ1 siRNA will be given to selectively bind CD206+ Macs linked to murine cGVHD/BO and Scl. Aim 3. Mac communication with fibroblasts/myofibroblasts causes fibrosis that can be halted by fibroblast activation protein (FAP) CAR Tregs. Utilizing our first of its kind cell atlas of disease progression, we will elucidate the nature of crosstalk between profibrogenic TGFβ-producing Macs, fibroblasts, myofibroblasts and endothelial cells culminating in tissue fibrosis. We show FAP upregulation in cGVHD lung (BO), skin (Scl) and cGVHD/Scl patients and will infuse FAP CAR Tregs to eliminate damaged cells. We will fill cGVHD pathophysiology knowledge gaps for mechanistic insights focused on T:B and Mac: fibroblast/myofibroblast/endothelial cell (fibrosis) crosstalk, test novel therapies in clinically relevant models and, with mature data, assist Dr. Pavletic to lead cGVHD CAR trials at the NIH Clinical Center using intramural funds

Up to $1.6M
2028-02-29
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

FindGrants Pro

Save unlimited matches with FindGrants Pro — $19/mo

Includes 1 application credit per month, weekly emailed grant alerts matching your org, and deadline reminders. Cancel anytime.

See Pro details

Found a grant that fits? Get matched to even more.

Answer a 2-minute questionnaire and our engine scores every grant in the database against your organization — surfacing opportunities you might miss browsing manually.

Get Personalized Matches — Free